期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型喹唑啉化合物的合成与生物活性 被引量：3

Synthesis and Application of Novel Intermediate of Quinazoline Compounds
下载PDF
导出
摘要 设计并合成4类新型喹唑啉化合物,进行医药和农药的联合筛选,生物活性测试表明部分新化合物具有较好的生物活性。 Four kinds of novel quinazoline compounds were designed and synthesized for the joint development of medicine and pesticides in this paper. The bioassay results showed that some new compounds had good inhibitory activity against growth of crop pathogenic fungi and ERK 1/2 phosphorylation of PC3 cells.
作者 薛伟 宋宝安 杨松 胡德禹 刘刚 刘平生 张培权 金林红 张素梅
机构地区 贵州大学精细化工研究开发中心
出处 《精细化工中间体》 CAS 2006年第6期16-19,共4页 Fine Chemical Intermediates
基金 国家重点基础研究发展计划"973"计划(2003CB114404) 国家自然科学基金(20442003 20562003) 贵州省省长资金项目资助
关键词 喹唑啉 中间体 生物活性 quinazoline intermediate bioactivity
分类号 O626 [理学—有机化学]
  • 相关文献

参考文献23

  • 1Armarego W L F.Quinazolines I V.Covalent Hydration in the Cations of Sustituted Quinazolines[J].J Chem.Soc.1962,561-572.
  • 2David J C,Declan C,Timothy P S,et al.Synthesis of Quinazolinones and Quinazolines[J].Tetrahedron.2005,61:10 153-10 202.
  • 3Denizot F,Lang R.Rapid Colorimetric Assay for Cell Growth and Survival.Modifications to the Tetrazolium Dye Procedure Giving Improved Sensitivity and Reliability[J].J.Immunol Methods.1986,89:271-277.
  • 4Edwards S G,Seddon B.Mode of Antagonism of Brevibacillus Brevis Against Botrytis Cinerea in Vitro[J].J Appl.Microbiol.,2001,91:652-659.
  • 5Endicott M M,Alden B W,Sherrill M L.Quinazoline derivatives.(Ⅲ) The Synthesis of 4-(3'-Diethylaminopropoxy)-6-chloroquinazoline (SN 12,254)[J].J.Am.Chem.Soc.1946,68:1 303-1 304.
  • 6Estrada E,Pena-A,Garcia-Domenech R.Designing Sedative/Hypnotic Compounds from a Novel Substructural Graph-theoretical approach[J].J.Comput-Aided Mol.Des.1998,12:583-595.
  • 7Huffman M A,Yasuda N,Decamp A E,et al.Asymmetric Synthesis of (S)-(-) -6-chloro-4-cyclopropyl-3,4-dihydro-4-((2-pyridyl)ethynyl)-2(1H)-quinazolinone[P].WO:9 513 273(US:5 434 152),1995.
  • 8Ibrahim S S,Abdel-Halim A M.Synthesis and Biological Evaluation of Some New Fused Quinazoline Derivatives[J].J Chem.Research (S) 1997,5:154-155.
  • 9Lee J Y,Park Y K,Seo S H,et al.1,4-Dioxane-fused 4-anilinoquinazoline as Inhibitors of Epidermal Growth Factor Receptor Kinase[J].Arch.Pharm.Pharm.Med.Chem.,2001,334:357-360.
  • 10Lee Y S,Park H K,Lee J Y,et al.4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline Derivatives and Process for Preparing the same[P].US:2 003 045 537,2003.

二级参考文献42

  • 1Baselga J, Yano K, Giaccone G, et al. Initial results from a phase trial of ZD 1839(Iressa) as second- and third-line monotherapy for patients with advanced nonsmall cell lung cancer (IDEAL 1 ). Clin Cancer Res,2001,7 (Suppl): 3780S.
  • 2Khuri FR, Rigas JR, Figlin RA, et al.Multi-institutional phase Ⅰ / Ⅱ trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol,2001,19(10) : 2626-2637.
  • 3Hidalgo M, Siu LL, Nemunaitis J, et al.Phase Ⅰ and pharmacologic study of OSI774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol,2001,19(13): 3267-3279.
  • 4Swisher SG, Roth JA, Komaki R, et al. A phase Ⅱ trial of adenoviral mediated p53gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2000,19 : 461a.
  • 5Kris MG, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in phase Ⅰ trails of oral ZD 1839 (lressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Canc
  • 6AwadaA, Gil T, De Valeriola D, et al. A Phase Ⅰ , clinical and pharmacokinetic trial of Zarnestra (farnesyl transferase inhibitor, R115777) and docetaxel: A promising combination in patients with solid tumors.Clin Cancer Res,2001,7 (Suppl): 3774S.
  • 7Sharma S, Kemeny N, Kelsen DP, et al.A phase Ⅱ trial of farnesyl protein transferase inhibitor SCH 66336, given by twicedaily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol,2002,1
  • 8Dickler MN, Ragupathi G, Liu NX, et al.Immunogenicity of a fucosyl-GMl-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res,1999,5(10): 2773-2779.
  • 9Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res,2000,6(12): 4607-4609.
  • 10Achiwa H, Yatabe Y, Hida T, et al.Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res,1999,5(5) : 1001-1005.

共引文献47

同被引文献47

  • 1王宏青,刘惠,刘钊杰.吡唑并嘧啶氧苯氧乙酸酯类化合物的合成与除草活性[J].有机化学,2004,24(12):1563-1568. 被引量：20
  • 2黄润秋,李慧英,马军安,邱德文.4－肟醚基喹唑啉类化合物的合成及其抗植物病毒TMV活性[J].高等学校化学学报,1996,17(4):571-574. 被引量：23
  • 3邵海舟,周蕴,夏敏.6,7-二甲氧基-4-(3′-三氟甲基)苯胺基喹唑啉的快速合成与体外活性测定[J].合成化学,2006,14(1):66-68. 被引量：3
  • 4孔凡彬,高扬帆,陈锡岭,李广领,陈军.9种药剂对玉米小斑病菌的室内抑菌试验[J].广西农业科学,2006,37(2):148-149. 被引量：34
  • 5Santagati N A, Bousquet E, Spadaro A, et al. 4- Quinazolinones: synthesis and reduction of prostaglandin E2 Production [J], IlFarmaco, 1999, 54 (11/12) : 780-784.
  • 6Pandeya S N, Sriram D, Nath G, et al. Synthesis antibacterial, antifungal and anti-HIV evaluation of Schiff and mannich bases of isatin derivatives with 3-amino-2- methylmercaptoquinazolin-4 (3H)-one [J].PharmActaHelv, 1999, 74 (11): 11-17.
  • 7Gineinah M M, El-Sherbeny M A, Nasr M N, et al. Synthesis and anti-inflammatory screening of some quinazoline and quinazoly-4-oxoquinazoline derivatives[J]. ArchPharm(Weinheim, Germany), 2002, 335 (11): 556-562.
  • 8Mishani E, Abourbeh G, Rozen Y, et al. Novel catbon-ll labeled 4-dimethylamino- but-2-enoci acid (4-(phenylamino)- quinazoline-6-yl)-amides : potential PET bioprobes for molecular imaging of EGFR-positive tumors [J]. Nuclear Medicine and Biology, 2004, 31: 469-476.
  • 9Bos M, Mendelsohn J, Kim Y M, et al. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor activation and inhibits growth of cancer cells in a receptor number-dependent manner[J]. Clin Cancer Res, 1997, 3 (11 ) : 2 099-2106.
  • 10Driscoll D, Steinkampf R, Patmore S, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD 183805 on vascular endothelial growth factor secretion from several tumor models[J]. Proc Am Assoc Cancer Res, 1999, 40: 121-127.

引证文献3

二级引证文献5

精细化工中间体
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部